Status:
WITHDRAWN
HIV Risk Reduction and Drug Abuse Treatment in Iran
Lead Sponsor:
Yale University
Collaborating Sponsors:
National Institute on Drug Abuse (NIDA)
Conditions:
Opiate Dependence
HIV Infections
Eligibility:
MALE
18-65 years
Phase:
PHASE2
Brief Summary
A randomized, double blind clinical trial comparing buprenorphine and naltrexone maintenance treatment when combined with drug abuse and HIV risk reduction counseling (DC-HIV) for heroin and opium add...
Detailed Description
This randomized double blind clinical trial compares the efficacy of buprenorphine maintenance treatment (BMT) and naltrexone maintenance treatment (NMT) for recently detoxified opioid dependent patie...
Eligibility Criteria
Inclusion
- Opioid Dependence
Exclusion
- Dependence on alcohol, benzodiazepines or sedatives
- Suicide or homicide risk
- Psychotic disorder or major depression
- Inability to read or understand the protocol or assessment questions
- Life-threatening or unstable medical problems
- Greater than 3 times normal liver enzymes (AST, GGT)
Key Trial Info
Start Date :
October 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2008
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00398008
Start Date
October 1 2004
End Date
December 1 2008
Last Update
March 30 2020
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Yale University School of Medicine
New Haven, Connecticut, United States, 06519
2
Institute for Cognitive Studies
Tehran, Iran